Observation of the clinical features of dupilumab-associated facial erythema

Hao Wu; Weiming Zhang; Zhongxiao Wu; Yanna Shen; Li Zhang; Mouzhe Yang; Yougang Ren; Feng Mao

doi:10.5114/ada.2023.132260

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2023
vol. 40

Send email

Copy url:

abstract:

Original paper

Observation of the clinical features of dupilumab-associated facial erythema

Hao Wu

¹

,

Weiming Zhang

²

,

Zhongxiao Wu

¹

,

Yanna Shen

¹

,

Li Zhang

¹

,

Mouzhe Yang

¹

,

Yougang Ren

¹

,

Feng Mao

¹

Department of Dermatology, Ningbo No. 6 Hospital, Ningbo, China
Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hubei, China

Adv Dermatol Allergol 2023; XL (6): 741-746

DOI: https://doi.org/10.5114/ada.2023.132260

Online publish date: 2024/01/08

View full text Get citation

Introduction:
Dupilumab is the first biologic agent used to clinically treat moderate and severe atopic dermatitis (AD) and is currently the only biologic agent used for this condition. Many studies have reported that moderate-to-severe AD was significantly improved after dupilumab injection, although head/neck dermatitis occurred with itching, flushing, and scaling. Moreover, because all the symptoms occur after dupilumab treatment, they are called “dupilumab facial redness (DFR)”.

Aim:
To retrospectively analyse the clinical characteristics and treatment of facial erythema in patients with atopic dermatitis treated with dupilumab.

Material and methods:
The clinical data of patients with moderate-to-severe atopic dermatitis treated with dupilumab (600 mg for the first time, 300 mg every 2 weeks thereafter) in the department of dermatology from July 2020 to May 2022 were obtained. We described their characteristics and analysed their symptomatic treatment measures and efficacy.

Results:
Twenty-one patients with DFR were included. Most clinical manifestations were erythema and pruritus, which differed from the symptoms of typical moderate-to-severe AD. After treatment, drug withdrawal, and dressing change, the symptoms of 17 patients were effectively controlled or completely improved, while these of 4 did not improve.

Conclusions:
Although the mechanism of DFR is still unclear, symptomatic treatment is partially effective, and medication discontinuation and switching to Janus kinase inhibitors are acceptable for some patients.

keywords:

Observation of the clinical features of dupilumab-associated facial erythema

Hao Wu 1 , Weiming Zhang 2 , Zhongxiao Wu 1 , Yanna Shen 1 , Li Zhang 1 , Mouzhe Yang 1 , Yougang Ren 1 , Feng Mao 1

atopic dermatitis, dupilumab, facial erythema, facial redness, flushing

Hao Wu

¹

,

Weiming Zhang

²

,

Zhongxiao Wu

¹

,

Yanna Shen

¹

,

Li Zhang

¹

,

Mouzhe Yang

¹

,

Yougang Ren

¹

,

Feng Mao

¹